Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference

Rhea-AI Summary

Cerus (Nasdaq: CERS) has announced that its Chief Financial Officer, Kevin Green, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference. The event will take place in Minneapolis on Wednesday, May 29th. This participation is a significant opportunity for Cerus to discuss its financial health and future outlook with key institutional investors.

Positive

• Cerus 's participation in a notable investor conference underscores its active engagement with the investment community.
• Presence at the Craig-Hallum Conference provides an opportunity to showcase financial stability and strategic outlook to institutional investors.
• The event could enhance investor confidence and potentially attract new institutional investments.

Negative

• The press release lacks specific financial or operational updates, leaving investors uncertain about recent performance metrics.
• Absence of detailed information on expected discussions or presentations could lead to investor interest.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 21^st Annual Craig-Hallum Institution Investor Conference in Minneapolis, on Wednesday, May 29^th.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522601002/en/

Jessica Hanover – Vice President, Corporate Affairs

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

What event is Cerus participating in?

Cerus is participating in the 21st Annual Craig-Hallum Institutional Investor Conference.

When is the 21st Annual Craig-Hallum Institutional Investor Conference?

The conference is on Wednesday, May 29th.

Who will represent Cerus at the Craig-Hallum Conference?

Kevin Green, the Chief Financial Officer of Cerus , will represent the company.

What is the significance of Cerus 's participation in the Craig-Hallum Conference?

Participation in the conference is significant for discussing the company's financial health and future outlook with institutional investors.

Where is the 21st Annual Craig-Hallum Institutional Investor Conference held?

The conference will be held in Minneapolis.